Amyloidosis
📧 Sign up to get email alerts when something new happens for Amyloidosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Vyndaqel (tafamidis) — Pfizer Europe MA EEIG
European Medicines Agency authorises Vyndaqel (tafamidis) for Amyloidosis via Pfizer Europe MA EEIG.
-
EMA approval · 2026-06-04EMA Authorised: Tegsedi (inotersen sodium) — Akcea Therapeutics Ireland Limited
Authorised: Tegsedi (inotersen sodium) by Akcea Therapeutics Ireland Limited for amyloidosis with orphan designation and accelerated assessm…
-
EMA approval · 2026-06-03EMA Authorised: Vyndaqel (tafamidis) — Pfizer Europe MA EEIG
Authorised status for Vyndaqel (tafamidis) from EMA, with orphan designation, for amyloidosis.
-
EMA approval · 2026-04-22EMA Authorised: Vyndaqel (tafamidis) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Vyndaqel (tafamidis) for amyloidosis, with Pfizer Europe MA EEIG as the marketing authorisation hol…
-
EMA approval · 2024-01-17EMA Authorised: Tegsedi (inotersen sodium) — Akcea Therapeutics Ireland Limited
EMA authorises Tegsedi (inotersen sodium) for amyloidosis, with orphan medicine designation and accelerated assessment.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.